Frank Calvosa is a Partner in Quinn Emanuel’s New York office. His practice involves intellectual property, with a focus on Hatch-Waxman patent litigation and related regulatory and antitrust issues on behalf of innovator pharmaceutical companies.
Frank has a Master’s degree in Chemistry and applies his scientific training to his patent litigation practice. He has litigated patent cases involving numerous diverse products, such as Pomalyst® (cancer treatment), Revlimid® (cancer treatment), Xyrem® (narcolepsy and cataplexy treatment), Nuedexta® (pseudobulbar affect treatment), Thalomid® (cancer and leprosy treatment), and Qsymia® (chronic weight management treatment).
Frank’s practice also includes post-grant patent review proceedings at the U.S. Patent and Trademark Office. He has experience with challenges in the pharmaceutical, chemical polymer, and medical device fields. In 2019, Frank was named by Patexia as one of the top 100 most active attorneys representing patent owners in inter partes reviews. Frank also has experience with post-grant proceedings before numerous international patent offices.
In addition to litigation, Frank counsels clients regarding FDA issues, patent-portfolio evaluation and analysis, the patentability of inventions, the validity of patents, and freedom-to-operate new technologies.
- Avanir Pharmaceuticals, Inc.
- Celgene Corporation
- Jazz Pharmaceuticals, Inc.
- Odonate Therapeutics
- Vivus, Inc.
- Representing Celgene Corporation in multiple Hatch-Waxman actions relating to its Pomalyst® (pomalidomide) drug product.
- Representing Celgene Corporation in multiple Hatch-Waxman actions relating to its Revlimid® (lenalidomide) drug product. The first-filer action settled favorably for Celgene in 2015.
- Represented Jazz Pharmaceutics, Inc. in multiple Hatch-Waxman actions relating to its Xyrem® (sodium oxybate) drug product against nine generic drug companies. All of the actions settled favorably for Jazz, with the last settlement taking place in October 2018.
- Represented Celgene Corporation in inter partes reviews challenging patents covering the active ingredient in and methods of using Celgene’s Revlimid® (lenalidomide) drug product. Successfully convinced the USPTO to deny institution of six such IPRs from 2015 through 2019.
- Represented Vivus, Inc. in multiple Hatch-Waxman actions relating to its Qsymia® (phentermine and topiramate-extended release) drug product. The actions settled favorably for Vivus in 2017.
- Represented Dow Chemical Company in inter partes reviews challenging patents covering chemical polymers used in paints. Obtained PTAB trial victories upholding the validity of all challenged claims. The decisions were affirmed on appeal in 2017.
- Represented Jazz Pharmaceuticals, Inc. in inter partes reviews challenging patents covering methods of using its Xyrem® (sodium oxybate) drug product. Successfully convinced the USPTO to deny institution of three such IPRs in 2016.
- Represented Jazz Pharmaceuticals, Inc. in connection with six covered business method patent reviews. In the first decisions of their kind, successfully convinced the USPTO to deny institution of all six proceedings in 2015.
- Represented Avanir Pharmaceuticals, Inc. in multiple Hatch-Waxman actions relating to its Nuedexta® (quinidine/dextromethorphan) drug product. Obtained trial victory in favor of Avanir, finding infringement and upholding the validity of Avanir’s patents for twelve years through 2026. The district court’s opinion was upheld by the Federal Circuit in August 2015 by a unanimous Rule 36 affirmance.
- Columbia Law School
- Harlan Fiske Stone Scholar
- Harlan Fiske Stone Scholar
- Villanova University
(M.S., Chemistry; 2008; B.S., summa cum laude, Chemistry, 2007)
- Phi Beta Kappa
- Jones Day:
- Associate, 2011– 2012